Category: Phase 2

TrueTear in Sjogren’s Disease Patients

https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst STUDY TITLE: TrueTear in Sjogren’s Disease Patients DESCRIPTION: Conditions:   Dry Eye Syndromes;   Sjogren’s SyndromeIntervention:   Device: TrueTear Intranasal Tear NeurostimulatorSponsors:   University of Pennsylvania;   AllerganCompleted CLINICALTRIALS.GOV IDENTIFIER: NCT03719885 FIRST POSTED: Thu, 25 Oct 2018 12:00:00 EDT LAST UPDATE POSTED: 08/25/20 07:09AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst STUDY TITLE: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome DESCRIPTION: Condition:   Sjögren SyndromeInterventions:   Drug: CFZ533;   Other: PlaceboSponsor:   Novartis PharmaceuticalsRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03905525 FIRST POSTED: Fri, 05 Apr 2019 12:00:00 EDT LAST UPDATE POSTED: 10/28/19 11:40AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies DESCRIPTION: Condition:   Sjogren’s SyndromeInterventions:   Drug: tofacitinib;   Other: PlaceboSponsor:   National Institute of Dental and Craniofacial Research (NIDCR)Not yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04496960 FIRST POSTED: Tue, 04 Aug 2020 12:00:00 EDT […]

Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS)

https://www.clinicaltrials.gov/ct2/show/NCT02962895 Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS) Brief Summary: This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters Condition or disease Intervention/treatment Phase Primary Sjogren Syndrome Biological: VAY736 Other: Placebo Phase 2 Study Design Go to sections Study Type : Interventional (Clinical Trial) […]

A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome [Completed]

https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst STUDY TITLE: A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome. DESCRIPTION: Condition:   Sjögren’s SyndromeInterventions:   Drug: TCM (Gan-Lu-Yin)GLY;   Drug: PLACEBOSponsor:   Chung Shan Medical UniversityCompleted CLINICALTRIALS.GOV IDENTIFIER: NCT04111341 FIRST POSTED: Tue, 01 Oct 2019 12:00:00 EDT LAST UPDATE POSTED: 10/01/19 06:22PM STUDY LINK / URL: https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst

An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome

https://www.clinicaltrials.gov/ct2/show/NCT03627065 A Study of INCB050465 in Primary Sjögren’s Syndrome Brief Summary: The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren’s syndrome (SS). Condition or disease Intervention/treatment Phase Primary Sjögren’s Syndrome Drug: Parsaclisib Phase 2 Study Design Go to sections Study Type : Interventional Estimated Enrollment […]